Quell Therapeutics was founded in March 2019 with the aim of developing engineered T regulatory (Treg) cell therapies. Tregs are a subset of T cells with the potential to downregulate the immune system. Quell was founded by Syncona in partnership with six leading experts in the Treg field.

Tregs are a subset of T cells with the potential to downregulate the immune system. Quell is seeking to utilise the power of Treg cells to advance therapies for the management and treatment of a range of conditions such as solid organ transplant rejection, autoimmune and inflammatory diseases.

Developing

Company Details

CEO:

Iain McGill

Syncona Representatives:

Martin Murphy
Elisa Petris
Freddie Dear